Preliminary Analysis of the Multiple Sclerosis Autonomy Scale (MSAS) Questionnaire Evaluating Patient Autonomy in Multiple Sclerosis (MS)

Speaker(s)

Donze C1, Mekies C2, Paillot G3, Brechenmacher L4, Civet A5, Pau D6, Bourel G4, Cimerman A4, Cohen M7, Mouzawak C8, Vermersch P9
1Hôpital Saint Philibert, Lille, France, 2Clinique des Cèdres, Toulouse, France, 3Aventure Hustive, Saint Malo, France, 4Roche SAS, Boulogne-Billancourt, France, 5Roche, Boulogne Billancourt, 92, France, 6Roche, BOULOGNE BILLANCOURT, 92, France, 7Hopital Pasteur 2, Nice, France, 8Réseau SEP IDF Ouest, Le Vésinet, France, 9University of Lille, CHU of Lille, Lille, France

Presentation Documents

OBJECTIVES: This study aimed at evaluating psychometric properties of a PROM dedicated to identifying impact of MS on patients’ autonomy. MSAS questionnaire has been developed with MS patients and healthcare professionals.

METHODS: This longitudinal prospective study included MS patients from Jan-2024 to May-2024 in 33 sites. MSAS questionnaire containing 10 dimensions in a 36-items short form (1 item of importance accorded to each dimension and 26 items assessing the impact dispatched within all dimensions) have to be completed by patients at inclusion, D15, D30 and D365.

The following scores are calculated (standardized scores on 0-100 scale, higher scores representing higher burden of autonomy):

  • Dimension_importance_score: mean dimension’s importance item, evaluating if the dimension is important to the patient.
  • Impact_Score: mean dimensions’ items score (except importance item), evaluating level of patient’s autonomy in the considered dimension.
  • Weighted_Impact_Scores: mean impact by importance.
This abstract focuses on MSAS score analysis at inclusion according to disease form.

RESULTS: 199 patients completed the MSAS questionnaire at baseline: 132 (66.3%) with relapsing remitting form of MS (RRMS), 23 (11.5%) with primary progressive (PPMS) and 44 (22.1%) with secondary progressive (SPMS).

Whatever the disease form, the most important dimension for patients was the support from partner (mean score of 89.5±15.6) and the consideration of the care team (mean score of 86.5±14.8).

Highest impact dimension score was involvement in an associative group for PPMS (67.1±37.9) and RRMS (49.4±34.4), participating in activities with others for SPMS (55.5±19.8).

Highest weighted global dimension score was participating in activities with others for PPMS (44.8±25.0) and SPMS (44.5±17.7), role as a grandparent for RRMS (38.5±26.3).

CONCLUSIONS: Highest scores of importance dimension, impact dimension items and weighted scores show different dimensions according to the form of MS. This will allow us to identify dimensions that really matter to focus on improving patients' autonomy.

Code

PCR13

Topic

Patient-Centered Research, Study Approaches

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes, Prospective Observational Studies

Disease

Neurological Disorders